合并后公司拥有以景助达及GB491治疗晚期或转移性HR+/HER2-乳腺癌的协同专营权。 本文为IPO早知道原创 嘉和生物向亿腾医药股东发行新股作为对价， 亿腾医药、嘉和生物在此次交易中的股权价值分别为 6.77亿美元和1.97亿美元。 亿腾医药股东将持有 合并公司 77.43%的股份，成为 合并公司的 控股 股东，而嘉和生物的股东则持有 其余 的 22.57%股份。 亿腾医药 从一家 CSO发展成综合型生物医药公司， 专注于在中国研究、开发及商业化具有巨大市 场需求的治疗药物。公司通过向跨国公司收购品牌药物资产，以及从全球生物制药公司授权引进创新 专利药物的开发及商业化权利，已建立多元化产品组合 ， 主要覆盖 抗感染、 CVD及呼吸系统 疾病 。 其主要产品包括 3 款 原研药 稳可信、希刻劳 、 亿瑞平 、 2款创新药 Vascepa 、 Mulpleta ， 及 其他产品包括 H景助达、罗可曼均已经实现商业化。 同时 ，亿腾 医药通过 获得跨国公司转让生产设施及管理体系并实施运营，拥有了 符合国际标准 的 制造、供应链管理、技术转移及质量控制体系。 公司在中国 31个省份拥有1000名销售代表，覆盖约1 ...

Core Viewpoint - Jiayou Bio-B (06998) has submitted a listing application to the Hong Kong Stock Exchange, marking the first reverse acquisition case of an innovative pharmaceutical company since the implementation of Rule 18A by the Hong Kong Stock Exchange [1] Group 1: Company Overview - Yiteng Pharmaceutical is a comprehensive professional biopharmaceutical company that has established a competitive and market-potential portfolio of original and innovative drugs through acquisitions of brand drug assets from multinational companies [1] - The product portfolio of Yiteng Pharmaceutical includes five main products, three of which are original products (Wenkexin, Xikelai, and Yirui Ping) and two innovative products (Vascepa and Mulpleta), all of which have been commercialized [1][2] Group 2: Financial Performance - Yiteng Pharmaceutical's revenue for the years ending December 31, 2022, 2023, and 2024 is projected to be 2.0738 billion, 2.3038 billion, and 2.5460 billion respectively, indicating steady sales growth driven by the strong performance and potential of its product portfolio [5] Group 3: Strategic Implications - The integration of Jiayou Bio's innovative R&D resources will enable Yiteng Pharmaceutical to accelerate the development and market promotion of innovative drugs, particularly the upcoming CDK4/6 inhibitor, which can synergize with Yiteng's existing HDAC inhibitor to explore broader market opportunities [5]